Welcome, Guest
Username: Password: Remember me
Cytori´s Platform applications
  • Page:
  • 1

TOPIC: Khanna session details

Khanna session details 20 Jan 2015 15:48 #3227

  • fas
  • fas's Avatar Topic Author
  • Offline
  • Moderator
  • Moderator
  • May the fat be with you
  • Posts: 3257
  • Thank you received: 1109
IR - i.e Shawn Richardson announced the availability of some detailed information on the Khanna session in San Francisco a week earlier.

Was even a formal announcement, which read as follows:

SAN DIEGO - Cytori Therapeutics, Inc. (NASDAQ: CYTX) announced today that information, presented last week in San Francisco, introducing its pivotal scleroderma trial (“the STAR trial”), is now available on the company website at www.Cytori.com . The information session featured Dr. Dinesh Khanna, Frederick G.L. Huetwell Professor of Rheumatology and Associate Professor of Internal Medicine in the Division of Rheumatology, and Director of the Scleroderma Program at the University of Michigan (med.umich.edu/scleroderma). Dr. Khanna is the Principal Investigator of Cytori’s STAR Trial. He has won numerous awards, including the 2007 Spirit of Leadership Award and the 2011 “Best Doctor of the Year” award from the Scleroderma Foundation.

The STAR trial will begin enrolling in 2015 and will include 80 patients in the United States. The trial is a randomized, double-blind, placebo-controlled study of the safety and efficacy of a single administration of Cytori’s lead cellular therapeutic, ECCS-50, in scleroderma patients with hand dysfunction.
“Scleroderma is a rare disease, affecting nearly 300,000 patients in the US. The systemic form, systemic sclerosis, is the focus of the STAR trial and has a prevalence of 60,000 – 70,000 patients. It is an agonizing disease that leads to hand impairment in nearly 90% of patients. Hand symptoms are the leading cause of disability in this patient population, more disabling than rheumatoid arthritis, and severely negatively impact quality of life and work productivity. In addition to general measures to protect the hand, patients require medications, which often are inadequate to control symptoms or prevent complications. This cohort of patients has a dire and unmet need for effective treatments,” explains Dr. Khanna.
The STAR trial is predicated on a completed pilot trial, SCLERADEC-I. In data published in the Annals of the Rheumatic Diseases 2014, patients in SCLERADEC-I showed at six months, on average, after a single treatment of 4 million cells injected into each finger, a 50 percent improvement across four important clinically relevant endpoints used to assess the clinical status in patients with systemic scleroderma with impaired hand function: improved hand function, decreased pain, improved Raynaud’s phenomena and health related quality of life.
“The scleroderma patient community anxiously awaits the development of therapeutics that will provide a better quality of life for people with this complex disease. I applaud the work of Cytori Therapeutics and their scientific partners as they work to bring important therapeutic advancements to people living with scleroderma” said Robert Riggs, CEO of Scleroderma Foundation, Inc.


The documentation is a bit hard to find, so I downloaded for you SEE ATTACHMENTS:

File Attachment:

File Name: Cytori2015_khanna_SF.pdf
File Size: 16,806 KB



File Attachment:

File Name: Cytori-BiotechSC-Sclero-Jan-2015.pdf
File Size: 2,198 KB
Attachments:

Please Log in or Create an account to join the conversation.

Board moderator and Site-owner. I still regret the day I started analysing the prospects of MacroPore (now Cytori) back in 2004- a left-over from the tech-bubble at that time from the century change in my portfolio- and became addicted to Cytori´s fat cell technology. :cry:

Khanna session details 21 Jan 2015 15:23 #3228

  • CalhounDoppelganger
  • CalhounDoppelganger's Avatar
  • Offline
  • Gold Boarder
  • Gold Boarder
  • Posts: 160
  • Thank you received: 20
“The scleroderma patient community anxiously awaits the development of therapeutics that will provide a better quality of life for people with this complex disease. I applaud the work of Cytori Therapeutics and their scientific partners as they work to bring important therapeutic advancements to people living with scleroderma” said Robert Riggs, CEO of Scleroderma Foundation, Inc.


Now this is the kind of relationships that Cytori needs to form. Happy to read this information.

Please Log in or Create an account to join the conversation.

Khanna session details 21 Jan 2015 16:16 #3229

  • fatboy
  • fatboy's Avatar
  • Offline
  • Platinum Boarder
  • Platinum Boarder
  • Posts: 416
  • Thank you received: 77
Dop,

After pissing away hundreds of millions of dollars (mainly on themselves) I hope this company through its products is finally able to help these poor people. I don't know anyone afflicted but it looks and sounds like a terribly painful and debilitating disease.

Please Log in or Create an account to join the conversation.

  • Page:
  • 1
Time to create page: 0.203 seconds

Copyright Information

Copyright Fas Kuiters © 2016 young-foxes.com. All Rights Reserved.
This page is made with Joomla CMS and its various templates designed by Fas Kuiters with the excellent Themler tool.

 

 

Shared Spreadsheet Links

DOV´s Revised Projections for the Periods 2017 until 2020

Shareble link : HERE

Fas Kuiters Websites